- Home
- CELC vs ACTG Comparison
CELC vs ACTG Comparison
Compare CELC & ACTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- ACTG
- Stock Information
- Founded
- CELC 2011
- ACTG 1993
- Country
- CELC United States
- ACTG United States
- Employees
- CELC N/A
- ACTG N/A
- Industry
- CELC Medical Specialities
- ACTG Multi-Sector Companies
- Sector
- CELC Health Care
- ACTG Miscellaneous
- Exchange
- CELC Nasdaq
- ACTG Nasdaq
- Market Cap
- CELC 440.0M
- ACTG 363.5M
- IPO Year
- CELC 2017
- ACTG 1996
- Fundamental
- Price
- CELC $13.04
- ACTG $3.74
- Analyst Decision
- CELC Strong Buy
- ACTG
- Analyst Count
- CELC 6
- ACTG 0
- Target Price
- CELC $30.67
- ACTG N/A
- AVG Volume (30 Days)
- CELC 196.9K
- ACTG 159.5K
- Earning Date
- CELC 08-13-2025
- ACTG 08-07-2025
- Dividend Yield
- CELC N/A
- ACTG N/A
- EPS Growth
- CELC N/A
- ACTG N/A
- EPS
- CELC N/A
- ACTG N/A
- Revenue
- CELC N/A
- ACTG $222,414,000.00
- Revenue This Year
- CELC N/A
- ACTG $141.36
- Revenue Next Year
- CELC N/A
- ACTG N/A
- P/E Ratio
- CELC N/A
- ACTG N/A
- Revenue Growth
- CELC N/A
- ACTG 65.22
- 52 Week Low
- CELC $7.58
- ACTG $2.70
- 52 Week High
- CELC $19.77
- ACTG $5.70
- Technical
- Relative Strength Index (RSI)
- CELC 60.10
- ACTG 54.75
- Support Level
- CELC $12.48
- ACTG $3.52
- Resistance Level
- CELC $13.60
- ACTG $3.79
- Average True Range (ATR)
- CELC 0.74
- ACTG 0.12
- MACD
- CELC 0.04
- ACTG -0.01
- Stochastic Oscillator
- CELC 75.91
- ACTG 62.86
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.